UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

6 Jan 2023

UCB announces rozanolixizumab BLA for the treatment of generalized myasthenia gravis filed with U.S. FDA and designated for Priority Review

Read More
23 Dec 2022

UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab

Read More
19 Dec 2022

FINTEPLA[®]▼ (fenfluramine) oral solution recommended for approval in the EU for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Read More
13 Dec 2022

UCB and Praxis Precision Medicines Announce Epilepsy Research Collaboration

Read More
12 Dec 2022

Changes in UCB’s Board of Directors

Read More
9 Dec 2022

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

Read More

Stay up-to-date on the latest news and information from UCB